Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma.
Affiliation
University Department of Medicine and Pharmacy, Hope Hospital, Salford.Issue Date
1988-09-24
Metadata
Show full item recordCitation
Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma. 1988, 297 (6651):772-3 BMJJournal
BMJDOI
10.1136/bmj.297.6651.772PubMed ID
3142542Type
ArticleLanguage
enISSN
0959-8138ae974a485f413a2113503eed53cd6c53
10.1136/bmj.297.6651.772
Scopus Count
Collections
Related articles
- Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study.
- Authors: Glover D, Lipton A, Keller A, Miller AA, Browning S, Fram RJ, George S, Zelenakas K, Macerata RS, Seaman JJ
- Issue date: 1994 Dec 1
- [Disodium pamidronate (APD) in the treatment of bone metastases].
- Authors: Costa L, Moreira C, da Costa EB
- Issue date: 1993 Feb
- Pain relief and sclerosis of bone metastases in a patient with breast cancer treated with tamoxifen, radiotherapy and pamidronate disodium: which treatment helped?
- Authors: Ripamonti C, Fulfaro F, Polastri D, De Conno F, Laffranchi A, Moliterni A
- Issue date: 1998 Aug
- Efficacy of pamidronate in breast cancer with bone metastases: a randomized double-blind placebo controlled multicenter study.
- Authors: Hultborn R, Gundersen S, Rydén S, Holmberg E, Carstensen J, Wallgren UB, Kilany S
- Issue date: 1996
- Reduction in calcium excretion in women with breast cancer and bone metastases using the oral bisphosphonate pamidronate.
- Authors: Dodwell DJ, Howell A, Ford J
- Issue date: 1990 Jan